MannKind employees including CEO Michael Castagna, center, ring the opening bell of the Nasdaq on May 23. (courtesy photo) Westlake Village-based MannKind Corporation capped off a record year with a fourth quarter to remember, beating analysts' estimates and setting up for a brighter future. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
